Results 21 to 30 of about 20,522 (204)

Ezetimibe ameliorates clinical symptoms in a mouse model of ankylosing spondylitis associated with suppression of Th17 differentiation

open access: yesFrontiers in Immunology, 2022
Ankylosing spondylitis (AS) is a chronic inflammatory disease that causes spinal inflammation and fusion. Although the cause of AS is unknown, genetic factors (e.g., HLA-B27) and environmental factors (e.g., sex, age, and infection) increase the risk of ...
Jeonghyeon Moon   +18 more
doaj   +1 more source

Expanding the therapeutic landscape: ezetimibe as non-statin therapy for dyslipidemia [PDF]

open access: yesThe Korean Journal of Internal Medicine, 2023
Dyslipidemia is a significant risk factor for atherosclerotic cardiovascular disease (ASCVD), and statins are the primary therapeutic options for reducing low-density lipoprotein cholesterol (LDL-C) levels.
Jeongmin Lee, Seung-Hwan Lee
doaj   +1 more source

Changes in cholesterol absorption and cholesterol synthesis caused by ezetimibe and/or simvastatin in men

open access: yesJournal of Lipid Research, 2009
This study evaluates changes in cholesterol balance in hypercholesterolemic subjects following treatment with an inhibitor of cholesterol absorption or cholesterol synthesis or coadministration of both agents. This was a randomized, double blind, placebo-
Thomas Sudhop   +8 more
doaj   +1 more source

Densitometric Determination of Ezetimibe in the Presence of its Alkaline Degradation Product [PDF]

open access: yesJournal of Advanced Pharmacy Research, 2018
Objectives: A simple, accurate, selective and sensitive densitometric method was developed for the determination of ezetimibe in the presence of its alkaline degradation product.
khalid Attia   +4 more
doaj   +1 more source

Low-density lipoprotein-cholesterol lowering effect of a nutraceutical regimen with or without ezetimibe in hypercholesterolaemic patients with statin intolerance

open access: yesFrontiers in Cardiovascular Medicine, 2022
BackgroundStatins are the most widely prescribed medication to lower low-density lipoprotein cholesterol (LDL-c). However, a significant portion of patients are unable to tolerate them due to side effects, most commonly muscle related.
Natalie C. Ward   +3 more
doaj   +1 more source

Ezetimibe [PDF]

open access: yesCirculation, 2018
Article, see p 1571 IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial), conducted in 18 144 participants who had recently experienced an acute coronary syndrome, demonstrated that the addition of ezetimibe 10 mg to simvastatin 40 mg, both taken daily, reduced low-density lipoprotein (LDL) cholesterol by an additional 16
William G, Herrington   +2 more
openaire   +3 more sources

Impact of combination therapy with statin and ezetimibe on secondary prevention for post-acute myocardial infarction patients in the statin era

open access: yesInternational Journal of Cardiology: Heart & Vasculature, 2015
Background: Little is known concerning the effect of ezetimibe for secondary prevention in post-myocardial infarction (MI) patients. In this study, we investigated the secondary prevention effect of ezetimibe for post-MI patients.
Soichiro Ebisawa   +14 more
doaj   +1 more source

Trends in Ezetimibe Prescriptions as Monotherapy or Fixed-Dose Combination in Germany 2012–2021

open access: yesFrontiers in Cardiovascular Medicine, 2022
AimsAddition of ezetimibe to statin therapy is recommended by current guidelines when low-density lipoprotein cholesterol (LDL-C) targets are not achieved with statin monotherapy.
Julius L. Katzmann   +7 more
doaj   +1 more source

Inhibition of Smooth Muscle Cell Proliferation by Ezetimibe via the Cyclin D1-MAPK Pathway

open access: yesJournal of Pharmacological Sciences, 2014
.: Proliferation of vascular smooth muscle cells (VSMCs) contributes to the development of atherosclerosis. Ezetimibe is a new lipid lowering agent that inhibits cholesterol absorption.
Li Qin   +9 more
doaj   +1 more source

Pharmacokinetics and bioequivalence of Ezetimibe tablet versus Ezetrol®:an open-label, randomized, two-sequence crossover study in healthy Chinese subjects

open access: yesBMC Pharmacology and Toxicology, 2023
Background Ezetimibe is a new class of antihyperlipidemic agent indicated for the prevention of atherosclerosis disease and for the treatment of hypercholesterolemia.
Feifei Sun   +10 more
doaj   +1 more source

Home - About - Disclaimer - Privacy